Welcome to our dedicated page for OS Therapies Incorporated news (Ticker: OSTX), a resource for investors and traders seeking the latest updates and insights on OS Therapies Incorporated stock.
OSTX (OS Therapies, Inc.) is an innovative biotechnology company committed to developing advanced therapies for the treatment of osteosarcoma, a rare and aggressive bone cancer primarily affecting children and young adults. The company leverages cutting-edge research and technology to create targeted treatments aimed at improving patient outcomes and quality of life.
OSTX's core business involves the development of novel immunotherapies and precision medicine. The company's flagship project, OST-01, is a groundbreaking immunotherapy designed to specifically target and eliminate osteosarcoma cells while sparing healthy tissue. This pioneering approach has shown promising results in preclinical studies and is currently in the early stages of clinical trials.
Recently, OS Therapies has secured significant funding and established strategic partnerships with leading research institutions and pharmaceutical companies. These collaborations are aimed at accelerating the development and commercialization of their therapeutic pipeline.
Financially, OS Therapies, Inc. has demonstrated robust growth and stability. The company's recent funding rounds have attracted major investors, underscoring confidence in OSTX's potential. This financial backing enables OSTX to expand its research efforts and bring its innovative treatments to market more rapidly.
OS Therapies is also actively engaged in several promising projects beyond OST-01. These include exploratory research into other rare cancers and potential applications of their immunotherapy platform. The company's commitment to scientific excellence and patient care continues to drive its mission forward.
Overall, OSTX is a key player in the biotechnology sector, dedicated to transforming the landscape of cancer treatment through innovation and collaboration. For investors and stakeholders, OS Therapies offers a compelling opportunity in the promising field of cancer immunotherapy.
OS Therapies (NYSE American: OSTX) announces the completion of the treatment period for its AOST-2121 Phase 2b clinical trial of OST-HER2 in recurred, resected Osteosarcoma. The last patient has completed their final 52-week radiographical evaluation. The company is preparing to request a Type C Meeting with the FDA and make any necessary protocol adjustments before locking the clinical trial database for data analysis.
The topline data readout is expected in Q4 2024. OST-HER2 is designed to prevent metastasis, delay recurrence, and increase overall survival in Osteosarcoma patients. The trial involved 41 patients across 21 U.S. sites, with primary endpoints of Event Free Survival at 12 months and Overall Survival at 36 months. OS Therapies will ring the closing bell at the NYSE, with CEO Paul Romness scheduled for interviews on Fintech.TV and the Schwab Network on October 3, 2024.
OS Therapies (NYSE American: OSTX) has announced the development of two novel tunable Antibody Drug Conjugate (tADC) therapeutic candidates using its proprietary SiLinker™ technology. The first candidate targets Breast, Lung, and Gastric Cancer, while the second focuses on platinum-resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. The company has completed target engagement tests for both candidates, confirming their therapeutic potential.
OS Therapies aims to advance its tADC platform through product development milestones and plans to out-license certain therapeutic candidates and components, particularly the ph-sensitive SiLinker™. The company's first tADC asset, OST-tADC-FRα-H, has achieved proof of concept in animal models of ovarian cancer. With these new additions to its pipeline, OS Therapies is positioning itself as a key provider of intellectual property for new therapeutic product development to partners.
OS Therapies (NYSE American:OSTX) has announced positive preclinical data for its ovarian cancer therapeutic candidate developed using its proprietary tunable Antibody Drug Conjugate (tADC) platform. The candidate, OST-tADC-FRA-H, combines a folate receptor alpha targeting small molecule with hexa-exatecan payloads linked by the company's SiLinker™ technology.
Key findings include:
- Strong antitumor activity in KB and IGROV-1 mouse models of ovarian cancer
- Excellent safety profile with no bodyweight loss compared to control animals
- Potential to improve safety and efficacy of existing ADC combinations
This proof-of-concept study paves the way for developing multiple tADC-based drug candidates for preclinical and clinical evaluation, potentially revolutionizing ADC construction.
OS Therapies (NYSE American: OSTX) has announced its participation in the H.C. Wainright 26th Annual Global Investment Conference, scheduled for September 9-11, 2024, in New York City. The company's President & CEO, Paul Romness, MPH, will deliver a virtual presentation highlighting:
- The company's potentially pivotal fully-enrolled Phase 2b trial of OST-HER2 for preventing resected, recurrent human osteosarcoma
- OST-HER2's pending pivotal safety study in treating canine osteosarcoma
- The company's tunable Antibody Drug Conjugate (tADC) therapeutic platform technology
The virtual presentation will be available starting at 7:00 AM ET on September 9, 2024. Interested parties can register for the conference at https://hcwevents.com/annualconference/.
OS Therapies (NYSE American: OSTX) announced the completion of treatment for the final patient in its Phase 2b clinical trial of OST-HER2 for recurred, resected Osteosarcoma. The trial, AOST-2121 (NCT04974008), enrolled 41 patients across 21 U.S. sites. The primary endpoint is 12-month Event Free Survival, with final evaluation expected in early Q4 2024. OST-HER2 is a Listeria-based immunotherapeutic vaccine designed to prevent metastasis and increase survival in Osteosarcoma patients.
The study aims to demonstrate efficacy in patients with high recurrence risk. Topline data, including 12-month Event Free Survival and interim 2-year Overall Survival, is anticipated in Q4 2024. This trial is significant as no new FDA-approved treatments have improved Osteosarcoma outcomes in over 40 years.
OS Therapies (NYSE American: OSTX) has appointed Borys Shor, PhD to its Antibody Drug Conjugate (ADC) Advisory Board. Dr. Shor will assist in selecting antibodies and payloads for the company's tunable ADC platform, which uses proprietary pH-sensitive SiLinker™ silicone linker technology. With 20 years of experience in oncology discovery programs, Dr. Shor brings expertise from roles at Pfizer, Wyeth, and as CEO of Manhattan BioSolutions. His background includes developing small molecule kinase inhibitors, biologics, and nanoparticles. At Pfizer, he led teams developing novel ADCs and supported the BLA filing for Inotuzumab, approved for leukemia treatment in 2017. Dr. Shor's appointment aims to strengthen OS Therapies' ADC development capabilities.
OS Therapies (NYSE American: OSTX), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, has issued a clarification regarding the CUSIP identifier of its common stock. The company's stock began trading on the NYSE American on August 1st, 2024, under CUSIP 68764Y108. On August 5th, due to a pre-listing corporate action, a new CUSIP 68764Y207 was assigned. All shares under the old CUSIP are now identified under the new CUSIP, with no share splits or similar actions occurring between August 1-5, 2024. OS Therapies urges all market participants, especially brokerage firms, to update their records accordingly.
OS Therapies (NYSE American: OSTX), a clinical-stage biopharmaceutical company, has been accepted into Johnson & Johnson Innovation – JLABS. The company aims to develop its tunable Antibody Drug Conjugate (ADC) linker-based platform at JLABS. This platform uses pH sensitive linkers & coating technology to reduce off-target effects, potentially improving safety and increasing the diversity of therapeutic payloads delivered.
OS Therapies' goal is to offer improved efficacy compared to other ADCs in the market or in development. The company's unique linker platform allows for the creation of new intellectual property for both novel and off-patent targeting antibodies and drug payloads. This development could potentially lead to more effective and safer ADC-based therapies in the future.
OS Therapies (NYSE American: OSTX) reported Q2 2024 financial results, highlighting a successful IPO on July 31, 2024, raising $6.4 million without issuing warrants. The company converted all outstanding preferred shares and debt into equity, resulting in 20.85 million common shares outstanding post-IPO. Key points include:
1. Cash runway extended into mid-2025
2. $1.557 million net operating loss in Q2 2024, down from $2.505 million in Q2 2023
3. Net loss per share of $0.26 on 5.991 million weighted average shares
4. Fully enrolled Phase 2b clinical trial for OST-HER2 in osteosarcoma, with results expected in Q4 2024
5. Positive safety data from Phase 1 study of OST-HER2 in breast cancer
RedChip Companies will air interviews with OS Therapies Inc. (NYSE American:OSTX) and Can-Fite BioPharma on Bloomberg TV on August 10, 2024, at 7 p.m. ET. Paul Romness, Chairman and CEO of OS Therapies, will provide a corporate update on the company's novel treatments for Osteosarcoma and other solid tumors. OS Therapies' product candidates, OST-HER2 and OST-tADC, aim to address gaps in pediatric and young adult cancer care. The company is approaching significant clinical milestones and potential revenue streams, including out-licensing deals and a priority review voucher valued at $100-110M.
FAQ
What is the current stock price of OS Therapies Incorporated (OSTX)?
What is the market cap of OS Therapies Incorporated (OSTX)?
What does OS Therapies, Inc. specialize in?
What is OSTX's flagship project?
How is OS Therapies funded?
What are some of OS Therapies' recent achievements?
What is the current status of OST-01?
What other projects is OS Therapies working on?
How does OS Therapies contribute to the field of cancer treatment?
Who are OS Therapies' partners?
What is the significance of OS Therapies' work?
Why should investors be interested in OSTX?
